AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations

Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) have become the standard care of patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC), development of acquired resistance is inevitable. A secondary mutation of threonine 790 (T790M) is associated with...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMC cancer 2016-07, Vol.16 (1), p.491-491, Article 491
Hauptverfasser:	Zhao, Ren, Zhou, Shun, Xia, Bing, Zhang, Cui-Ying, Hai, Ping, Zhe, Hong, Wang, Yan-Yang
Format:	Artikel
Sprache:	eng
Schlagworte:	Analysis Animals Antineoplastic Agents, Phytogenic - therapeutic use Apoptosis - drug effects bcl-X Protein - antagonists & inhibitors Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Cell Line, Tumor Cell Proliferation - drug effects Cell Survival - drug effects Diagnosis Drug Synergism Female Gefitinib Gene mutations Genetic aspects Gossypol - analogs & derivatives Gossypol - therapeutic use Humans Influence Lung cancer Lung cancer, Non-small cell Lung Neoplasms - drug therapy Lung Neoplasms - pathology Mice Mice, Inbred BALB C Mice, Nude Myeloid Cell Leukemia Sequence 1 Protein - antagonists & inhibitors Protein Kinase Inhibitors - therapeutic use Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors Quinazolines - therapeutic use Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Epidermal Growth Factor - biosynthesis Receptor, Epidermal Growth Factor - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!